Tesla stock has continued to rise steadily as from February. However, significant changes in its stock prices were evident from February 20th to April 4th. The performance of the company’s stock has been influenced by its electric model 3 unveiling. This is a mass-market automobile that is expected to pose stiff competition to other automobiles such as Audi, Mercedes-Benz, Lexus, which are gas-powered and similarly priced as the model 3. The only company that is producing an electric automobile similar to Tesla’s is General Motors. In just these two months, the company stocks jumped with over 100 dollars from $144- the lowest stock price since the close of 2013- to almost a whopping $255.
The luxurious electric vehicle produced by the company has been turning heads as the company has been able to generate a similar hype equal to the one that was produced by iPhone. Many investors have been in the run to buy Tesla shares as the company holds a bright future. For instance, in the middle of weekdays, people are seen lining up in Manhattan to reserve the Tesla’s Model 3. On the other hand, people in Brooklyn cramped out. Even though the stock prices might fall in future, investors do not want to suffer the effects of regret tinged math. For instance, if one had purchased only ten shares back in 2013, right now the person would be one grand richer. The more the shares, the higher the price. By the year 2020, the company is projected to have delivered 370,000 vehicles. Given the fact that reservations have already been made, the company is going to be doing better and building its profit daily. Therefore, as heads carry on turning at the same pace, the stock of the company will continue rising. Out of twenty analysts who polled, nine of them benchmarked Tesla a buy or a strong buy while five benchmarked it a hold. This is clear evidence that the company will continue doing better.
Medici Nova Inc., which is a biopharmaceutical company, has also experienced a rise in its stock prices. The company’s intention of acquiring as well as developing small molecule and novel therapeutics for treating severe diseases that already have unmet medical needs for American markets. This has made the company prices to soar since then with stocks rising over ninety percent since the year began. The stocks have successfully hit a 52 week high this morning. On February 22nd, the company’s stock prices were influenced by its announcement that MN-166 ALS abstract had been accepted for a dual presentation that was taking place at the American Academy of Neurology. Investors and analysts saw this as a bold step by the company which would have a positive effect on the company’s annual profits.
Another factor that led to the good performance of the Medici Nova Inc. stocks is the announcement of positive finding got from completion of phase 1b of MN-166 clinical trial in Methamphetamine dependence. The drug had shown significant results in reducing the subjective impacts of methamphetamine in individuals diagnosed with the dependence of methamphetamine. This was a successful step for the drug and that there was a possibility of higher sales to be made when the drug is officially released to the market. This increased the stock prices of the company. Stock analysts have been terming the company as a strong buy or a buy for the last three months. On February 20th, the company shares had an adjusted closing stock price of $4.85 but on April 4th, the adjusted close price was $9 ("MNOV Historical Prices | Medicinova, Inc. Stock - Yahoo! Finance").
Work cited
"MNOV Historical Prices | Medici Nova, Inc. Stock - Yahoo! Finance". Finance.yahoo.com. N.p., 2016. Web. 7 Apr. 2016.
